Type 1 diabetes mellitus induced by sintilimab: a case report and related case literature analysis.

Authors

Hao Su, Xinyu Zhao, Huayu Liu, Mianli Li, Haitao Geng

Published in

Frontiers in endocrinology. Volume 17. Pages 1881986. Epub Jul 01, 2026.

Abstract

Immune checkpoint inhibitors are widely used in the treatment of malignant tumors. Although the incidence rate of type 1 diabetes induced by these inhibitors is low, the damage to pancreatic β cells is irreversible and the treatment effect of steroids is poor, which requires clinical attention. This article reports a case of a 69-year-old patient with poorly differentiated adenocarcinoma of the stomach and colon who developed this disease during treatment with Sintilimab combined with the SOX regimen. After insulin treatment, her blood glucose levels gradually stabilized. Based on the literature, we explore the pathogenesis, diagnostic difficulties, and current treatment status centered around insulin replacement therapy. We emphasize the need for clinicians to strengthen blood glucose monitoring during treatment with immune checkpoint inhibitors, identify symptoms early, and optimize diagnosis and treatment to improve patient prognosis.

PMID:
42460315
Bibliographic data and abstract were imported from PubMed on 16 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.